Crown Bioscience has appointed John Gu as our new Chief Executive Officer (CEO). Following his tenure as interim CEO and his role as Chief Operating Officer (COO), John Gu is recognized as an esteemed leader with broad business acumen and extensive experience in digital strategy, business transformation, and genomic data analysis. His unparalleled experience is particularly relevant in streamlining AI-driven approaches to advance drug discovery and development processes, marking him as a remarkable asset in steering Crown Bioscience to the forefront of biotechnological innovation.
We're excited to share the news of Indivumed Services' complete integration with Crown Bioscience. This strategic move, following the acquisition in 2023, solidifies our standing in oncology drug research and development. As a result of this merger, the Indivumed Services brand will be fully retired in February 2025. https://www.crownbio.com/about-us/news-and-events/crown-bioscience-completes-merger-with-indivumed-services
We are proud to announce that our Hamburg site in Germany has been awarded continued accreditation to the globally recognized ISO 15189:2022 standard by the College of American Pathologists (CAP). This distinction underscores our unwavering dedication to quality and demonstrates technical excellence in laboratory services. The ISO 15189 standard provides laboratories with a rigorous framework for quality management, risk assessment, and continuous improvement. Accreditation is based on stringent requirements specific to medical laboratories. Our commitment to these standards affirms our focus on reducing risk and enhancing patient safety. Read more about this achievement: https://www.crownbio.com/about-us/news-and-events/crown-bioscience-germany-gmbh-achieves-continued-cap-151892022-accreditation
🏆 We have been honored with the 2024 Fierce Biotech CRO Award for Excellence in Client Service and Partnership. This prestigious award recognizes our outstanding collaboration, communication, and commitment to delivering excellence for our life sciences clients. We stood out for our innovative preclinical research capabilities, transparent communication practices, and unwavering focus on delivering quality and value to clients. Specific achievements highlighted include our Customer Satisfaction Program, which generates unfiltered feedback scores to demonstrate a strong commitment to service and customer excellence.
📣We're proud to be the recipient of the BioTech Breakthrough Award in the Biopharma category for innovation in drug development. This prestigious award highlights the achievements of our OrganoidXplore™ screening platform in advancing preclinical and translational oncology research. OrganoidXplore has emerged as the leading organoid panel screening service by processing more than 100 oncology models in six weeks, significantly expediting the drug development process with its rapid, data-driven decision-making capabilities. Utilizing a comprehensive selection of Patient-Derived Organoids (PDO) and Patient-Derived Xenograft Organoids (PDXO), the platform delves into the diversity of cancer tumors to aid in the discovery of novel cancer treatments and to facilitate more personalized therapeutic approaches.
📣We are excited to announce the beginning of the Eureka Network Eurostars Myeloid SIGNATUREs (MY-SIGNATURE) project. This initiative aims to tackle prostate cancer, particularly metastatic castration-resistant prostate cancer (mCRPC), a disease that leads to approximately 110,000 fatalities each year in Europe. The project, which received a €1.75 million grant, will focus on developing a novel liquid biopsy test—the first to detect intratumoral myeloid-derived suppressor cell (MDSC) infiltration—and could become pivotal in overcoming therapy resistance, a substantial challenge in cancer treatment. Crown Bioscience joined Novigenix SA, the project's lead partner, alongside the expertise from Radboudumc, to develop the MYELO-SCAN test. This liquid biopsy technology will harness the power of a novel transcriptomic biomarker, enabling enhanced patient stratification and an estimated 30% improvement in treatment outcomes. Read more in our news release https://www.crownbio.com/about-us/news-and-events/prostate-cancer-breakthrough
We are delighted to announce a strategic partnership with Clinical Trial & Consulting Services (CTI), a renowned global full-spectrum research service provider, to bolster oncology-focused consulting services. This collaboration unites decades of expertise from both organizations in oncology drug discovery and development, leveraging Crown Bioscience’s preclinical and translational models and CTI’s well-established track record in the clinical and regulatory space. Customers will benefit from combined expert guidance, supporting the transition of oncology compounds from discovery through early-phase clinical trials more rapidly and effectively. This alliance aims to determine the optimal and most expeditious path to the clinic, ensure long-term drug development success and growth, and accelerate the delivery of superior oncology therapeutics to patients.
📣We are delighted to announce the completion of a global collaboration agreement with the Shanghai Model Organisms Center (SMOC). This five-year agreement extends the existing partnership and will provide unique immuno-oncology platforms and services from all Crown Bioscience facilities worldwide. This strategic alliance includes: ✅The purchase and supply of a broad range of genetically engineered mouse models, including thousands of knock-in and knock-out humanized models, ✅Genetically engineered cell line development services, ✅Custom development of GEMM models and MuPrime™ (our tumor homograft models) leveraging SMOC-engineered mice. Globally, Crown Bioscience research affiliates will benefit from uniform pricing, comprehensive IP protection, and licensing rights. This uniformity is accompanied by a shared commitment to research excellence, unrivaled quality standards, and scientific innovation.
📣We are proud to announce our pivotal role in several scientific innovation projects funded by European grants. These projects aim to advance cancer treatments and the development of the tools to do so, employing cutting-edge techniques such as organoid and ex vivo patient tissue technologies, with the goal of bridging the gap between research and patient care. With collaborative efforts among small and medium-sized businesses, academic institutions, and enterprise companies, these initiatives will enhance R&D partnerships and advance the development and commercialization of lead compounds and novel oncology therapeutics.
📣We are delighted to announce that we have received CAP Accreditation; ISO 15189 Standard, for our Quality Medical Laboratory Services in Hamburg, at our Indivumed Services facility. In addition, our Suzhou site has recently been awarded CAP accreditation for biomarker laboratory services, covering areas such as surgical pathology, tissue processing, and complex solid tumor molecular sequencing. Our VP of Global Quality and Regulatory Compliance, Pam Shang, had this to say: ‘’The pace at which we progressed from initial gap assessment to CAP Accreditations was unparalleled, highlighting our robust quality management framework and technical proficiency. This further demonstrates our goal to uphold the highest standards of quality management systems and customer satisfaction.” Read the full release here ➡️ https://www.crownbio.com/about-us/news-and-events/crown-bioscience-achieves-cap-15189-accreditation
